| Home | About Us | Resources | Archive | Free Reports |
Weekend EditionBy S&A ResearchSaturday, January 17, 2009 Phase 1 analyst Rob Fannon assures us these big takeovers aren't an anomaly – we'll see tons of them this year. Big medical companies have more cash than they can spend, and hundreds of smaller medical companies need cash to survive. Rob is currently working on a list of companies with great drugs and debt problems that are likely to be bought out this year... Each company on this list could potentially double your money.
How likely is he to pick the companies that will be acquired? Well, so far this year, our biotech analysts have picked 70% of them... The two most recent takeovers produced triple-digit gains for subscribers.
We're about to enter one of the largest biotech bull markets of our lifetime, and early investors will make outrageous sums of money.
These are like superhero investments. Each has 10 consecutive years of net profits, 20 consecutive years of uninterrupted dividend payments, earnings growth in the past decade of at least 33%, and price-to-earnings and price-to-book multiples of less than 15.
For perspective, Grant notes that at the bottom of the Nasdaq bust in 2003, only two stocks met all those criteria. At the bottom of the market in 1991, only six qualified. (Since 1991, those six produced average annual returns of almost 19%.) If you bought just these eight stocks and forgot about them for a decade, chances are better than 90% you'll make a substantial return and beat the market. Usually, that's a lot harder to do.
Pretty much everything else we want is much cheaper now, too... big old convertible cars, condos in Miami, prime steaks, first-class airfare, grand cru wines. We love a good recession.
Right now, his employer is so desperate, the company is literally giving away free money: 0% financing with no minimum payment for 12 months. The catch is that, if you don't pay it off in 12 months, your interest rate goes to 21.9% – retroactive to the date of purchase. Imagine all the folks who'll spend $2,000 only to suddenly have a balance of more than $2,400 staring them in the face. My friend's company could wind up with a lot of scratched-up 13-month-old furniture coming back a year from now.
Sounds just like housing, doesn't it? Cheap financing suddenly gets expensive, resulting in a tsunami of defaults – subprime, teaser-rate, option-ARM furniture financing. This will appeal precisely to those who ought to avoid it.
True Wealth readers know Steve Sjuggerud is wildly bullish on corporate debt, especially "high-yield" debt. You can collect 20% yields in high-yield debt now. And there's a chance for capital gains, too. The enormous yield and profit potential more than make up for the added default risk. The chart below, from Steve's January issue, shows just how attractive these bonds are...
![]() This is truly a once-in-a-lifetime opportunity to safely collect 20% yields.
Regards,
S&A Research
|
Date Range:1/12/2009 to 1/17/2009
Date Range:1/12/2009 to 1/17/2009
|